Risk factors for bone metastasis in completely resected non-small-cell lung cancer-Reference-Cited by-同舟云学术

Risk factors for bone metastasis in completely resected non-small-cell lung cancer

Published:2017-04 Issue:8 Volume:13 Page:695-704
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Wang Hui¹,Zhang Yan²,Zhu Hui²,Yu Jinming²

Affiliation:

1. Shandong University, Jinan, Shandong Province, China

2. Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, China

Abstract

Aim: We assessed risk factors for bone metastasis in patients with completely resected non-small-cell lung cancer (NSCLC). Materials & methods: A total of 374 NSCLC patients who had undergone a complete resection from January 2008 to May 2012 were included in this retrospective study. The Kaplan–Meier method and multivariate Cox regression analysis were used to evaluate risk factors for bone metastasis. Results: A total of 47 (47/374; 12.6%) patients developed bone metastasis up until the last follow-up time. The patients with bone metastasis included 33 adenocarcinoma patients and 6 (4.9%) squamous cell carcinoma patients (p = 0.001). There were 17 (10.2%) patients with pathological stage (P-stage) I disease, 9 (9.5%) patients with P-stage II disease and 21 (18.8%) patients with P-stage III disease (p = 0.007) among all the bone metastasis patients. For patients without or with bone metastasis, the overall survival ratio at 3 years was 71.6% compared with 46.8% (p < 0.0001), respectively. Conclusion: Adenocarcinoma and P-stage III disease were related to a high risk of bone metastasis.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2016-0237

Reference32 articles.

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. www.scirp.org/reference/ReferencesPapers.aspx?ReferenceID=1210719.

2. The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

3. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. NCCN Clinical Practice Guideline in Oncology: Non-Small Cell Lung Cancer (2014). www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No Prognostic Impact of Staging Bone Scan in Patients with Stage IA Non–Small Cell Lung Cancer;2023-09-22

2. Prediction of bone metastasis in non-small cell lung cancer based on machine learning;Frontiers in Oncology;2023-01-09

3. Active demethylation upregulates CD147 expression promoting non-small cell lung cancer invasion and metastasis;Oncogene;2022-02-07

4. Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value;Frontiers in Oncology;2021-10-14

5. Soft coral-derived Aspernolide A suppressed non-small cell lung cancer induced osteolytic bone invasion via the c-Fos/NFATC1 signaling pathway;Journal of Thoracic Disease;2021-10